Dong-A ST said it has completed the global phase 3 clinical trial of DMB-3115, a biosimilar referencing Janssen’s plaque psoriasis treatment Stelara (ingredient: ustekinumab).The company initially initiated the global phase 3 clinical trial of DMB-3115 in the U.S. in 2021 and expanded it to eight ot
SK Bioscience, one of Korea’s leading vaccine makers, said it donated 3 billion won ($2.2 million) to the International Vaccines Institute (IVI) on Wednesday to advance global vaccine research and development.The donation will be used to support vaccine R&D, equipment, and device purchases, it added
CHA Vaccine Institute announced it is developing a mixed vaccine to prevent Covid-19 and influenza at the 2022 Hwasun International Vaccine Forum last Friday.The research institute said the combination vaccine aims to improve convenience and preventive effects for the elderly. The candidate substanc
LegoChem Bioscience said it signed an antibody-drug conjugate (ADC) joint research and development agreement with NextCure, a U.S. pharmaceutical company.Under the accord, the two companies plan to discover new ADC anticancer drugs by utilizing Next Cure's B7-H4 antibody and LegoChem's ADC platform
Roche Korea’s Tecentriq (atezolizumab) has expanded its indication to postoperative adjuvant therapy for the first time among lung cancer immunotherapies but fell short of expectations, industry watchers said on Wednesday.Last Friday, the Ministry of Food and Drug Safety approved the use of Tecentri
Middle Eastern countries including such as the United Arab Emirates (UAE) and Saudi Arabia are becoming major importers of Korean biopharmaceutical products.According to the Korea Customs Service's import and export statistics on Tuesday, exports of medical supplies, including pharmaceuticals and di
United Pharm is about to apply for the regulatory approval of a combo therapy, which combines the antithrombotic ingredient of cilostazol with the dyslipidemia component of rosuvastatin.Industry insiders pay attention to whether Korea United Pharm, which emerged as a significant player in the antith
Dx&Vx, a Korean molecular diagnostics company, said Wednesday that it recorded 8.6 billion won ($ 6.4 million) in sales in the third quarter, up 82.8 percent from the same period in 2021.The company also registered 412.2 million and 620.8 million won in operating and net profit, down 56.5 and 67.8 p
Some Korean biopharmaceutical companies have benefited from local currency weakening against the dollar in the second half, mainly due to their large proportions of exports, while importers of drug ingredients suffered headwinds.The Korean won has been sliding against the greenback throughout 2022.
Hanmi Pharmaceutical said on Monday that its U.S. partner, Aptose Bioscience, confirmed complete remission in phase 1/2 clinical trials of HM43239, an acute myeloid leukemia (AML) treatment (ingredient: tuspetinib), in all three doses (80 mg, 120 mg, and 160 mg). The trials took place in the U.S. an
Tecentriq (atezolizumab), an anti-PD-L1 drug developed by Roche, has become the first immunotherapy in Korea approved as a postoperative adjuvant treatment for early non-small cell lung cancer (NSCLC) patients.Last Friday, the Ministry of Food and Drug Safety approved the use of Tecentriq as the “po
The International Vaccine Institute (IVI) completed the second week of the three-week-long WHO Global Training Hub for Biomanufacturing (GTH-B) training program with a visit to Celltrion’s factory in Songdo, Incheon, on Friday.This training program is the second WHO GTH-B program following the first
SK Biopharmaceuticals, which targets the U.S. market with its epilepsy treatment, Cenobamate (XCopri in the U.S.), is stepping up the development of follow-up products.The Ministry of Food and Drug Safety approved the phase 3 clinical trial of SK Biopharmaceuticals’ Carisbamate (YKP509) last Thursda
Ildong Pharmaceutical has jumped into developing P-CAB (potassium-competitive acid blockers)-based treatment for gastroesophageal reflux disease (GERD), drawing the industry’s attention to the market once again.Last Thursday, the Ministry of Food and Drug Safety approved the domestic phase 1 trial o
M2N said it has established MGFB, a joint venture between Greenfire Bio (GFB), a U.S. affiliate of M2N and the Mayo Clinic, to jointly research and develop a solid cancer treatment using an anticancer vaccine.Through MGFB, the two parties plan to research an anticancer vaccine, under development by
A new treatment method developed by domestic researchers and improved overall survival (OS) of progressive biliary tract cancer patients in primary treatment has won approval from the government’s regulator.On Thursday, the Ministry of Food and Drug Safety approved the combination therapy of Imfinzi
SK Bioscience's Covid-19 vaccine, SKYCovione, is struggling to sell in Korea because of the introduction of bivalent booster vaccines by multinational pharmaceutical companies, such as Moderna and Pfizer, government data showed.According to the "Covid-19 Vaccination Safety Report," released by the K
Merck Korea, a leading science and technology company, said on Thursday that it appointed Christoph Hamann as general manager of Merck Biopharma Korea.Hamann previously served as managing director of Malaysia and general manager of Merck Biopharma in Malaysia, Singapore, and Brunei.Since joining Mer
Processa Pharmaceuticals, the U.S. partner of Yuhan Corp., has released part of the U.S. phase 2a clinical trial result data of YH12852 (PCS12852), a candidate substance to treat gastrointestinal diseases.Yuhan said Thursday that Processa has secured positive clinical results concerning improving ga
Bepirovirsen, which showed a possibility as hepatitis B’s complete cure in the interim analysis of phase 2b clinical trial results in June, saw its efficacy fall by at least 60 in recent data.Still, GSK said it expects Bepiroviren to become a treatment option providing a complete functional cure for